Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism

Tay–Sachs and Sandhoff diseases are clinically similar neurodegenerative disorders. These two sphingolipidoses are characterized by a heritable absence of β–hexosaminidase A resulting in defective GM2 ganglioside degradation. Through disruption of the Hexa and Hexb genes in embryonic stem cells, we have established mouse models corresponding to each disease. Unlike the two human disorders, the two mouse models show very different neurologic phenotypes. Although exhibiting biochemical and pathologic features of the disease, the Tay–Sachs model showed no neurological abnormalities. In contrast, the Sandhoff model was severely affected. The phenotypic difference between the two mouse models is the result of differences in the ganglioside degradation pathway between mice and humans.

[1]  K Suzuki,et al.  Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Capecchi,et al.  Altering the genome by homologous recombination. , 1989, Science.

[3]  G. Schwarzmann,et al.  Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects. , 1985, European journal of biochemistry.

[4]  R. Proia,et al.  Structure and Expression of the Mouse β-Hexosaminidase Genes, Hexa and Hexb , 1994 .

[5]  G. Schwarzmann,et al.  A simple and novel method for tritium labeling of gangliosides and other sphingolipids. , 1978, Biochimica et biophysica acta.

[6]  van den Eijnden Dh.  Chromatographic separation of gangliosides on precoated silicagel thin-layer plates. , 1971 .

[7]  L. Riboni,et al.  The Degradative Pathway of Gangliosides GM1 and GM2 in Neuro2a Cells by Sialidase , 1995, Journal of neurochemistry.

[8]  K. Sandhoff,et al.  Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. , 1979, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[9]  R. Jaenisch,et al.  Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system , 1992, Cell.

[10]  K. Sandhoff,et al.  Activating proteins for ganglioside GM2 degradation by beta-hexosaminidase isoenzymes in tissue extracts from different species. , 1983, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[11]  K. Sandhoff,et al.  A particle-bound sialyl lactosidoceramide splitting mammalian sialidase. , 1967, Biochimica et biophysica acta.

[12]  K. Sandhoff,et al.  Biochemical basis of late-onset neurolipidoses. , 1991, Developmental neuroscience.

[13]  K. Sandhoff,et al.  The biochemistry of sphingolipid storage diseases. , 1977, Angewandte Chemie.

[14]  K. Sandhoff,et al.  Over-expression of a functionally active human GM2-activator protein in Escherichia coli. , 1993, The Biochemical journal.

[15]  K. Sandhoff,et al.  ENZYME ALTERATIONS AND LIPID STORAGE IN THREE VARIANTS OF TAY‐SACHS DISEASE , 1971, Journal of neurochemistry.

[16]  B. Harvald,et al.  Adenosine-triphosphatase deficiency in a family with non-spherocytic haemolytic anaemia. , 1971, Human Heredity.

[17]  Yoshiyuki Suzuki,et al.  GM2‐gangliosidosis with total hexosaminidase deficiency , 1971, Neurology.

[18]  Kinuko Suzuki.  Neuropathology of Late Onset Gangliosidoses , 1991 .